Bertram L. Kasiske
Research Subjects
Bertram L. Kasiske has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
J. J. Snyder
Minneapolis Medical Research Foundation Scientific Registry of Transplant Recipients Minneapolis MN
10 shared publicationsA. K. Israni
Minneapolis Medical Research Foundation Scientific Registry of Transplant Recipients Minneapolis MN
9 shared publicationsJon J. Snyder
9 shared publicationsAjay K. Israni
5 shared publicationsN. Salkowski
Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN
5 shared publicationsBarbara Danielson
Department of Medicine, Hennepin County Medical Center, Minneapolis, MN, USA
4 shared publications
Latest Publications
- Open Access
- 16 January 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (5) , 1643-1650
Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States
The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non‐HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3‐month delay before granting a MELD exception score of 25, (2) a 6‐month delay before granting a score of 28, and (3) a 9‐month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n = 28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person‐years for the current policy and for 3‐, 6‐, and 9‐month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non‐HCC candidates. Conclusion: A delay of 6‐9 months would eliminate the geographic variability in the discrepancy between HCC and non‐HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates. (Hepatology 2015;61:1643–1650)
- 16 January 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (5) , 1643-1650
Open AccessDelayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States
The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC. The aim of this study was to evaluate the potential effects of delays in granting these exception points on transplant rates for HCC and non‐HCC patients. We used Scientific Registry of Transplant Recipients data and liver simulated allocation modeling software and modeled (1) a 3‐month delay before granting a MELD exception score of 25, (2) a 6‐month delay before granting a score of 28, and (3) a 9‐month delay before granting a score of 29. Of all candidates waitlisted between January 1 and December 31, 2010 (n = 28,053), 2773 (9.9%) had an HCC MELD exception. For HCC candidates, transplant rates would be 108.7, 65.0, 44.2, and 33.6 per 100 person‐years for the current policy and for 3‐, 6‐, and 9‐month delays, respectively. Corresponding rates would be 30.1, 32.5, 33.9, and 34.8 for non‐HCC candidates. Conclusion: A delay of 6‐9 months would eliminate the geographic variability in the discrepancy between HCC and non‐HCC transplant rates under current policy and may allow for more equal access to transplant for all candidates. (Hepatology 2015;61:1643–1650)
- 1 September 2014
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 64 (3) , 335-337
Outcomes After Living Kidney Donation: What We Still Need to Know and Why
- 1 September 2014
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 64 (3) , 335-337
Outcomes After Living Kidney Donation: What We Still Need to Know and Why
- Open Access
- 1 June 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (6) , 1271-1276
Bayesian Methods for Assessing Transplant Program Performance
- 1 June 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (6) , 1271-1276
Open AccessBayesian Methods for Assessing Transplant Program Performance
- Open Access
- 1 June 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (6) , 1310-1317
A Scientific Registry of Transplant Recipients Bayesian Method for Identifying Underperforming Transplant Programs
- 1 June 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (6) , 1310-1317
Open AccessA Scientific Registry of Transplant Recipients Bayesian Method for Identifying Underperforming Transplant Programs
- 1 March 2014
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 9 (3) , 562-571
The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant
There is a shortage of kidneys for transplant, and many patients on the deceased donor kidney transplant waiting list would likely benefit from kidneys that are currently being discarded. In the United States, the most common reason given for discarding kidneys retrieved for transplant is procurement biopsy results. This study aimed to compare biopsy results from discarded kidneys with discard attributed to biopsy findings, with biopsy results from comparable kidneys that were successfully transplanted. In this retrospective, observational, case-control study, biopsy reports were examined from 83 kidneys discarded in 2010 due to biopsy findings (cases), 83 contralateral transplanted kidneys from the same donor (contralateral controls), and 83 deceased donors randomly matched to cases by donor risk profile (randomly matched controls). A second procurement biopsy was obtained in 64 of 332 kidneys (19.3%). The quality of biopsy reports was low, with amounts of tubular atrophy, interstitial inflammation, arteriolar hyalinosis, and acute tubular necrosis often not indicated; 69% were wedge biopsies and 94% used frozen tissue. The correlation between first and second procurement biopsies was poor; only 25% of the variability (R(2)) in glomerulosclerosis was explained by biopsies being from the same kidney. The percentages of glomerulosclerosis overlapped substantially between cases, contralateral controls, and randomly matched controls: 17.1%±15.3%, 9.0%±6.6%, and 5.0%±5.9%, respectively. Of all biopsy findings, only glomerulosclerosis>20% was independently correlated with discard (cases versus contralateral controls; odds ratio, 15.09; 95% confidence interval, 2.47 to 92.41; P=0.003), suggesting that only this biopsy result was used in acceptance decisions. One-year graft survival was 79.5% and 90.7% in contralateral and randomly matched controls, respectively, versus 91.6% among all deceased donor transplants in the Scientific Registry of Transplant Recipients. Routine use of biopsies could lead to unnecessary kidney discards.
- 1 March 2014
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 9 (3) , 562-571
The Role of Procurement Biopsies in Acceptance Decisions for Kidneys Retrieved for Transplant
There is a shortage of kidneys for transplant, and many patients on the deceased donor kidney transplant waiting list would likely benefit from kidneys that are currently being discarded. In the United States, the most common reason given for discarding kidneys retrieved for transplant is procurement biopsy results. This study aimed to compare biopsy results from discarded kidneys with discard attributed to biopsy findings, with biopsy results from comparable kidneys that were successfully transplanted. In this retrospective, observational, case-control study, biopsy reports were examined from 83 kidneys discarded in 2010 due to biopsy findings (cases), 83 contralateral transplanted kidneys from the same donor (contralateral controls), and 83 deceased donors randomly matched to cases by donor risk profile (randomly matched controls). A second procurement biopsy was obtained in 64 of 332 kidneys (19.3%). The quality of biopsy reports was low, with amounts of tubular atrophy, interstitial inflammation, arteriolar hyalinosis, and acute tubular necrosis often not indicated; 69% were wedge biopsies and 94% used frozen tissue. The correlation between first and second procurement biopsies was poor; only 25% of the variability (R(2)) in glomerulosclerosis was explained by biopsies being from the same kidney. The percentages of glomerulosclerosis overlapped substantially between cases, contralateral controls, and randomly matched controls: 17.1%±15.3%, 9.0%±6.6%, and 5.0%±5.9%, respectively. Of all biopsy findings, only glomerulosclerosis>20% was independently correlated with discard (cases versus contralateral controls; odds ratio, 15.09; 95% confidence interval, 2.47 to 92.41; P=0.003), suggesting that only this biopsy result was used in acceptance decisions. One-year graft survival was 79.5% and 90.7% in contralateral and randomly matched controls, respectively, versus 91.6% among all deceased donor transplants in the Scientific Registry of Transplant Recipients. Routine use of biopsies could lead to unnecessary kidney discards.
- Open Access
- 1 January 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (1) , 178-183
The Equitable Allocation of Deceased Donor Lungs for Transplant in Children in the United States
- 1 January 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (1) , 178-183
Open AccessThe Equitable Allocation of Deceased Donor Lungs for Transplant in Children in the United States
- 27 November 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (4) , 763-769
Kidney Disease: Improving Global Outcomes--an update
Kidney Disease: Improving Global Outcomes (KDIGO) was founded in 2003 to fulfill a need for international cooperation and consolidation in the development and implementation of clinical practice guidelines. KDIGO has experienced a rapid growth in the development of guidelines, producing three guidelines in its first 6 years and another six in the last 3 years. In addition, it has held 12 global conferences on important issues in kidney disease and its treatment. A major effort is under way to support the dissemination and implementation of KDIGO guidelines through various channels, including an Implementation Task Force with official representatives in 86 countries. KDIGO is now under its own management and remains committed to the development of evidence-based guidelines. Future challenges include finding adequate sources of funding and building stronger links with other organizations involved in guideline development and implementation.
- 27 November 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (4) , 763-769
Kidney Disease: Improving Global Outcomes--an update
Kidney Disease: Improving Global Outcomes (KDIGO) was founded in 2003 to fulfill a need for international cooperation and consolidation in the development and implementation of clinical practice guidelines. KDIGO has experienced a rapid growth in the development of guidelines, producing three guidelines in its first 6 years and another six in the last 3 years. In addition, it has held 12 global conferences on important issues in kidney disease and its treatment. A major effort is under way to support the dissemination and implementation of KDIGO guidelines through various channels, including an Implementation Task Force with official representatives in 86 countries. KDIGO is now under its own management and remains committed to the development of evidence-based guidelines. Future challenges include finding adequate sources of funding and building stronger links with other organizations involved in guideline development and implementation.
- Open Access
- 25 October 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (1) , 5-9
Implications of predonation GFR to recipient and donor outcomes
Enthusiasm for living kidney donation has grown considerably over the past two decades as an ever-expanding waiting list demand has outstripped organ supply, while the number of living kidney donations in the USA has more than doubled during that time to nearly 6000 in 2011 [1], this growth is largely attributable to an increase in older donors (those aged 54 and above), who tend, on average, to have lower kidney function. Therefore, the implications of lower predonation kidney function on graft outcomes are increasingly relevant, and require careful scrutiny.
- 25 October 2013
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (1) , 5-9
Open AccessImplications of predonation GFR to recipient and donor outcomes
Enthusiasm for living kidney donation has grown considerably over the past two decades as an ever-expanding waiting list demand has outstripped organ supply, while the number of living kidney donations in the USA has more than doubled during that time to nearly 6000 in 2011 [1], this growth is largely attributable to an increase in older donors (those aged 54 and above), who tend, on average, to have lower kidney function. Therefore, the implications of lower predonation kidney function on graft outcomes are increasingly relevant, and require careful scrutiny.
- 1 September 2013
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 62 (3) , 577-586
A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up
- 1 September 2013
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 62 (3) , 577-586
A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up
- 1 March 2013
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 61 (3) , 371-374
The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset
- 1 March 2013
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 61 (3) , 371-374
The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset